Although we focused on the potential implications of CHIT1 inhibition in the context of asthma severity and airway remodeling, other enzymes hold therapeutic promise for glycosylation regulation, such as galectins, NEU1, and FUT2. The gene discussed is NEU1; the disease is asthma.